Succeeding in today’s crowded healthcare market often requires that associations align with like-minded organizations to achieve their goals. It is this realization that has led to a strategic partnership between The Lynx Group and the National Association of Specialty Pharmacy (NASP).
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
MedImpact Healthcare Systems, Inc. and Onco360 today announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based Oncology pharmaceutical care.
Results 1 - 6 of 6